Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
暂无分享,去创建一个
David Tuck | Vinay Varadan | Hannah Gilmore | Lyndsay N Harris | E. Winer | L. Harris | V. Bossuyt | Hannah Gilmore | S. Parsai | V. Varadan | D. Tuck | W. Sikov | G. Somlo | I. Krop | K. Miskimen | Ian E Krop | Eric P Winer | George Somlo | Kristy L S Miskimen | M. Abu-Khalaf | William Sikov | Veerle Bossuyt | Maysa M Abu-Khalaf | Shikha Parsai | Amad Awadallah | Mary Anne Fenton | A. Awadallah | M. Fenton
[1] D. Berry,et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Lähdesmäki,et al. Tubulin- and actin-associating GIMAP4 is required for IFN-γ secretion during Th cell differentiation , 2014, Immunology and cell biology.
[3] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[4] S. Ménard,et al. Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.
[5] J. Olson,et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[7] T. Kute,et al. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing , 2009, Cancer Immunology, Immunotherapy.
[8] I. Gibbs,et al. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] Charles M. Perou,et al. Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer , 2014, Clinical Cancer Research.
[12] S. Varga,et al. Quantifying Antigen-Specific CD4 T Cells during a Viral Infection: CD4 T Cell Responses Are Larger Than We Think , 2011, The Journal of Immunology.
[13] C. Denkert,et al. Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy , 2011, Seminars in Immunopathology.
[14] R. Gelber,et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.
[15] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[16] F. Esteva,et al. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development , 2014, British Journal of Cancer.
[17] Benjamin Haibe-Kains,et al. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.
[18] L. Gianni,et al. The immune system and response to HER2-targeted treatment in breast cancer. , 2014, The Lancet. Oncology.
[19] J. Isola,et al. Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance , 2007, Molecular Cancer Therapeutics.
[20] Jong-Hyeon Jeong,et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] yang-xin fu,et al. Effective Anti-Neu–Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells , 2013, Clinical Cancer Research.
[22] Mark T. W. Ebbert,et al. A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.
[23] E. Winer,et al. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. , 2015, Clinical breast cancer.
[24] D. Berry,et al. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). , 2014 .
[25] L. Harris,et al. Biomarkers for Predicting Response to Anti-HER2 Agents. , 2016, Advances in experimental medicine and biology.
[26] Sung-Bae Kim,et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. , 2014, The Lancet. Oncology.
[27] Krishna R. Kalari,et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Carlos L. Arteaga,et al. Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.
[30] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[31] E. Winer,et al. Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer. , 2012 .
[32] E. Winer,et al. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer , 2007, Clinical Cancer Research.
[33] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.